(Q83612533)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22403811%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

title

NICE guidance on rituximab for first-line treatment of symptomatic stage III-IV follicular lymphoma in previously untreated patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22403811%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22403811%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

author name string

Sally Doss

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22403811%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Zoe Garrett

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22403811%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Frances Sutcliffe

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22403811%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

publication date

1 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22403811%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

25 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22403811%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22403811%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22403811%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

128-130

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22403811%20AND%20SRC:MED&resulttype=core&format=json

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma

25 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970009-8

7 January 2021

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970009-8

7 January 2021

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970009-8

7 January 2021

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970009-8

7 January 2021

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970009-8

7 January 2021

Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970009-8

7 January 2021

10.1016/S1470-2045(12)70009-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22403811%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference